The efficacy of the anticancer drug vemurafenib, which is used to treat metastatic melanoma, is plagued by acquired resistance. A picture of how such resistance develops is emerging. See Letter p.387
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bollag, G. et al. Nature 467, 596–599 (2010).
Chapman, P. B. et al. N. Engl. J. Med. 364, 2507–2516 (2011).
Flaherty, K. T. et al. N. Engl. J. Med. 363, 809–819 (2010).
Poulikakos, P. I. et al. Nature 480, 387–390 (2011).
Gray-Schopfer, V., Wellbrock, C. & Marais, R. Nature 445, 851–857 (2007).
Wellbrock, C., Karasarides, M. & Marais, R. Nature Rev. Mol. Cell Biol. 5, 875–885 (2004).
Udell, C. M., Rajakulendran, T., Sicheri, F. & Therrien, M. Cell. Mol. Life Sci. 68, 553–565 (2011).
Wagle, N. et al. J. Clin. Oncol. 29, 3085–3096 (2011).
Johannessen, C. M. et al. Nature 468, 968–972 (2010).
Nazarian, R. et al. Nature 468, 973–977 (2010).
Kobayashi, S. et al. N. Engl. J. Med. 352, 786–792 (2005).
Nardi, V., Azam, M. & Daley, G. Q. Curr. Opin. Hematol. 11, 35–43 (2004).
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. Nature 464, 427–430 (2010).
Heidorn, S. J. et al. Cell 140, 209–221 (2010).
Hatzivassiliou, G. et al. Nature 464, 431–435 (2010).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lavoie, H., Therrien, M. A drug-resistant duo. Nature 480, 329–330 (2011). https://doi.org/10.1038/480329a
Published:
Issue Date:
DOI: https://doi.org/10.1038/480329a
